Novo Nordisk application for oral Wegovy accepted by USFDA for weight loss Ruchika Sharma3 May 2025 3:21 PM ISTPlainsboro: Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submission for an...
GLP-1 Drugs May Increase Rejection Risk in Lung Transplant Recipients, Study Suggests Dr. Shravani Dali3 May 2025 7:30 AM ISTA recent study presented at the 2025 International Society for Heart and Lung Transplantation (ISHLT) annual meeting suggests that glucagon-like...
Semaglutide has potential for treating fatty liver disease highlights VCU-led research Dr. Kamal Kant Kohli2 May 2025 8:30 AM ISTAn international study led by the director of Virginia Commonwealth University's liver institute suggests that the substance in Ozempic and Wegovy can...
Torrent Pharmaceutical Gets CDSCO Panel Nod To study Semaglutide Tablets Dr. Divya Colin26 April 2025 6:15 PM ISTNew Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Semaglutide promising alternative treatment for chronic myopathy of hyperkalemic periodic paralysis: a case report Dr Kartikeya Kohli21 April 2025 9:00 AM ISTSemaglutide promising alternative treatment for chronic myopathy of hyperkalemic periodic paralysis suggests a case report published in the BMC...
Conduct CT in India: CDSCO Panel tells Novo Nordisk India For new formulation of Semaglutide tablets Dr. Divya Colin17 April 2025 5:30 PM ISTNew Delhi: In line with the proposal for approval of Semaglutide tablets 1.5 mg, 4 mg, 9 mg of new formulation based on the bioequivalence (BE)...
Lean muscle mass loss minimized during weight loss therapy using newer incretin obesity drugs, suggests study Dr. Kamal Kant Kohli11 April 2025 9:15 AM ISTNew research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or...
Semaglutide Boosts Walking Capacity in PAD and Type 2 Diabetes, STRIDE Trial Finds Medha Baranwal3 April 2025 9:15 AM ISTUSA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with peripheral artery disease (PAD)...
Study Links Semaglutide to Increased NAION Risk in Diabetes Patients Medha Baranwal29 March 2025 7:45 AM ISTTaiwan: A recent cohort study published in JAMA Ophthalmology suggests that patients with diabetes who use semaglutide may face an increased risk of...
Anti-Obesity Drugs Tirzepatide and Semaglutide Offer Health Benefits but Cost found prohibitive: New Research Shows Medha Baranwal20 March 2025 9:30 AM ISTUSA: A recent economic evaluation has highlighted the significant long-term health benefits of tirzepatide and semaglutide in managing obesity among...
No Long-Term Safety Data: CDSCO Panel Denies Novo Nordisk's proposal to amend warning statement of Semaglutide Dr. Divya Colin16 March 2025 5:15 PM ISTNew Delhi: Citing that there is no real world long-term safety data for Novo Nordisk's antidiabetic drug Semaglutide tablets (3 mg, 7 mg, 14 mg), the...
Anti-obesity drugs benefit kidney transplant recipients with type 2 diabetes: Study Dr. Kamal Kant Kohli15 March 2025 9:00 AM ISTKidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and...
